WILMINGTON, Del., June 16, 2024--Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favorable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL).
This FTSE 100 stock recently unveiled plans to almost double revenue to $80bn by 2030. Our writer explores what this means for investors. The post Is this FTSE 100 behemoth about to make investors rich all over again? appeared first on The Motley Fool UK.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.